Cipla’s launch of Afrezza, India’s first inhalable insulin, marks a transformative milestone in diabetes care within the country. Developed by MannKind Corporation, Afrezza provides a needle-free, rapid-acting insulin alternative that is inhaled through a compact device, offering convenience and reducing the barriers posed by injectable therapies.
This innovative approach targets adults with type 1 and type 2 diabetes, particularly those struggling with needle aversion or adherence issues. Its rapid onset of action helps better manage post-meal blood sugar spikes, potentially improving overall glycemic control.
Given India’s staggering diabetes prevalence, with millions requiring insulin therapy, this introduction could significantly enhance accessibility to advanced and patient-friendly treatment options, aligning with Cipla’s commitment to transforming healthcare outcomes.